Brief: Scynexis- Co And Glaxosmithkline Intellectual Property Entered Binding MoU

Scynexis

02/01/2024 21:16

Jan 2 (Reuters) - SCYNEXIS Inc  SCYX.O :
    * SCYNEXIS INC - ON DECEMBER 26, CO AND GLAXOSMITHKLINE
INTELLECTUAL PROPERTY LTD ENTERED BINDING MOU
    * SCYNEXIS INC - BINDING MOU FOR AMENDMENT TO EXCLUSIVE
LICENSE
AGREEMENT BETWEEN SCYNEXIS AND GSK, DATED MARCH 30, 2023
    * SCYNEXIS INC: UNDER UPDATED LICENSE AGREEMENT, CO ALSO
ELIGIBLE
TO RECEIVE POTENTIAL REGULATORY APPROVAL MILESTONE PAYMENTS OF
UP TO $49 MILLION
    * SCYNEXIS-UNDER DEAL, CO GRANTED GSK EXCLUSIVE
ROYALTY-BEARING,
SUBLICENSABLE LICENSE FOR DEVELOPMENT,MANUFACTURE,&
COMMERCIALIZATION OF IBREXAFUNGERP
    * SCYNEXIS-UNDER DEAL,GRANTED GSK LICENSE FOR IBREXAFUNGERP
FOR
ALL INDICATIONS IN ALL COUNTRIES EXCEPT GREATER CHINA,COUNTRIES
LICENSED TO THIRD PARTIES

Further company coverage:  SCYX.O 

 ((Reuters.Briefs@thomsonreuters.com;))